Identification of KDM4C as a gene conferring drug resistance in multiple myeloma

Bortezomib (BTZ), a proteasome inhibitor, is a promising therapeutic option for multiple myeloma (MM) patients. However, drug resistance often occurs, leading to disease relapse and poor prognosis. In this study, we aimed to identify novel genes associated with drug resistance and investigate their...

Full description

Saved in:
Bibliographic Details
Published in:Open life sciences 2024-04, Vol.19 (1), p.20220848-20220848
Main Authors: Zhang, Na, Lan, Ruilong, Chen, Yingyu, Hu, Jianda
Format: Article
Language:English
Subjects:
bortezomib
drug resistance
hematologic cancer
KDM4C
multiple myeloma
proteasome inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bortezomib (BTZ), a proteasome inhibitor, is a promising therapeutic option for multiple myeloma (MM) patients. However, drug resistance often occurs, leading to disease relapse and poor prognosis. In this study, we aimed to identify novel genes associated with drug resistance and investigate their roles in BTZ resistance. Through the screening of 26 genes frequently associated with chemosensitivity or drug resistance, we discovered that KDM4C, a histone demethylase, exhibited increased expression in BTZ-resistant MM cells compared to their sensitive counterparts. Overexpression of enhanced the tolerance of a MM cell line to the drug, whereas the knockdown of , using shRNA, increased the sensitivity of resistant cells to BTZ treatment. This suggests that KDM4C plays a pivotal role in conferring BTZ resistance. Our study offers fresh insights into BTZ resistance in MM and highlights as a potential target for overcoming drug resistance.
ISSN:2391-5412
2391-5412
DOI:10.1515/biol-2022-0848